



Published in final edited form as:

Neurobiol Dis. 2019 January ; 121: 163–176. doi:10.1016/j.nbd.2018.09.026.

***Wwox* deletion leads to reduced GABA-ergic inhibitory interneuron numbers and activation of microglia and astrocytes in mouse hippocampus**

Tabish Hussain^a, Hyunsuk Kil^a, Bharathi Hattiangady^{b,c}, Jaeho Lee^a, Maheedhar Kodali^{b,c}, Bing Shuai^{b,c}, Sahithi Attaluri^{b,c}, Yoko Takata^a, Jianjun Shen^a, Martin C. Abba^d, Ashok K. Shetty^{b,c,1}, C. Marcelo Aldaz^{a,*,1}

^aDepartment of Epigenetics and Molecular Carcinogenesis, Science Park, The University of Texas MD Anderson Cancer Center, Smithville, TX, United States

^bInstitute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M Health Science Center College of Medicine, Temple and College Station, TX, United States

^cResearch Service, Olin E. Teague Veterans' Medical Center, CTVHCS, Temple, TX, United States

^dCINIBA, School of Medicine, UNLP, La Plata, Argentina

Abstract

The association of WW domain-containing oxidoreductase *WWOX* gene loss of function with central nervous system (CNS) related pathologies is well documented. These include spinocerebellar ataxia, epilepsy and mental retardation (SCAR12, OMIM: 614322) and early infantile epileptic encephalopathy (EIEE28, OMIM: 616211) syndromes. However, there is complete lack of understanding of the pathophysiological mechanisms at play. In this study, using a *Wwox* knockout (*Wwox KO*) mouse model (2 weeks old, both sexes) and stereological studies we observe that *Wwox* deletion leads to a significant reduction in the number of hippocampal GABA-ergic (γ -aminobutyric acid) interneurons. *Wwox KO* mice displayed significantly reduced numbers of calcium-binding protein parvalbumin (PV) and neuropeptide Y (NPY) expressing interneurons in different subfields of the hippocampus in comparison to *Wwox* wild-type (*WT*) mice. We also detected decreased levels of Glutamic Acid Decarboxylase protein isoforms GAD65/67 expression in *Wwox* null hippocampi suggesting lower levels of GABA synthesis. In addition, *Wwox* deficiency was associated with signs of neuroinflammation such as evidence of activated microglia, astrogliosis, and overexpression of inflammatory cytokines *Tnf- α* and *Il6*. We also performed comparative transcriptome-wide expression analyses of neural stem cells grown as

*Corresponding author at: Department of Epigenetics and Molecular Carcinogenesis, Science Park, The University of Texas MD Anderson Cancer Center, 1808 Park Road 1C, Smithville, TX 78957, United States, maaldaz@mdanderson.org (C.M. Aldaz). Author contributions

C.M.A. and A.K.S. designed research; T.H., H.K., B.H. J.L., M.K., B.S. Y.T. performed research; J.J., supervised next generation sequencing; T.H, C.M.A. and M.A. analyzed the data. T.H. and C.M.A. wrote the paper.

¹Co-senior authors.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nbd.2018.09.026>.

Conflict of interest

The authors declare no competing financial interests.

neurospheres from hippocampi of *Wwox KO* and *WT* mice thus identifying 283 genes significantly dysregulated in their expression. Functional annotation of transcriptome profiling differences identified ‘neurological disease’ and ‘CNS development related functions’ to be significantly enriched. Several epilepsy-related genes were found differentially expressed in *Wwox KO* neurospheres. This study provides the first genotype-phenotype observations as well as potential mechanistic clues associated with *Wwox* loss of function in the brain.

Keywords

Wwox; Epilepsy; Hippocampus; GABA-ergic interneurons; Microgliosis; Astrogliosis

1. Introduction

WW domain-containing oxidoreductase (*WWOX*) is a member of the short-chain dehydrogenase/reductase (SDR) protein superfamily (Bednarek et al., 2000). It spans the common fragile site FRA16D in chromosome region ch16q23.1–23.2 (Bednarek et al., 2000; Ried et al., 2000). *WWOX* was originally described by our and other laboratories as a putative tumor suppressor gene associated tumor progression, and therapy resistance in multiple cancer types [Reviewed in (Aldaz et al., 2014; Schrock et al., 2017)]. In more recent studies, *WWOX* has been recognized for its role in a much wider array of human pathologies including metabolic conditions and central nervous system (CNS) related syndromes (Aldaz et al., 2014; Chang et al., 2014; Mallaret et al., 2014).

Findings of *Wwox* protein expression and distribution in embryonic and adult murine nervous system highlighted a previously unidentified role of this protein in the normal development and function of CNS (Chen et al., 2004). *WWOX* protein expression was also observed in various neuronal cell types and regions from the human brain and cerebellum (Nunez et al., 2006). In 2007 Gribaa et al. described a novel childhood onset recessive spinocerebellar ataxia, epilepsy and mental retardation syndrome (cataloged as SCAR12, OMIM: 614322) affecting children from a large consanguineous family and the defective locus was mapped to chromosomal region ch16q21-q23 (Gribaa et al., 2007). Later, in 2014 Mallaret et al. by using whole exome sequencing, identified *WWOX* as the culprit defective gene in SCAR12. All probands of the family described by Gribaa et al. and from an additional consanguineous family carrying homozygous loss of function germline mutations affecting *WWOX* suffered from SCAR12 (Mallaret et al., 2014). Soon thereafter, other groups reported new familial cases of *WWOX* homozygous loss of function associated with early infantile epileptic encephalopathy (EIEE28, OMIM: 616211) also known as WOREE syndrome (*WWOX*-related epileptic encephalopathy) (Abdel-Salam et al., 2014; Ben-Salem et al., 2015; Mignot et al., 2015; Tabarki et al., 2015; Valduga et al., 2015; Elsaadany et al., 2016). Most of these familial cases are characterized by homozygous missense, non-sense, or splice site mutations combined in some cases with deletions ultimately leading to *WWOX* loss of function (Mignot et al., 2015). In most cases of complete loss of *WWOX* function (e.g. homozygous non-sense mutations) patients presented severe brain structural defects and died within the first two years of life (Abdel-Salam et al., 2014; Ben-Salem et al., 2015; Tabarki et al., 2015; Valduga et al., 2015). Consistent with observations in humans, we

reported that *Wwox* gene deletion leads to epileptogenesis and early death in mice, where all mice die by approximately 3 weeks of age (Ludes-Meyers et al., 2009; Mallaret et al., 2014). This is also in agreement with previous observations in rats spontaneously mutated at the *Wwox* locus (Suzuki et al., 2009). Notably, while the association of *WWOX* with CNS pathology is evident from the multiple human and rodent studies, there is complete lack of understanding on the pathophysiological mechanisms associated with *WWOX* loss of function in brain.

Clinical and experimental studies have demonstrated a clear association between certain types of epilepsy and hippocampal structural alterations (Schwartzkroin, 1994). Activated microglia and astrogliosis, are among the most evident deleterious changes affecting hippocampus function as a consequence of epileptic seizures (Devinsky et al., 2013). Thus, in this study, using *Wwox KO* mice we investigated the effects of *Wwox* deletion in affecting the abundance of hippocampal GABA-ergic inhibitory interneurons while investigating effects on inflammatory markers such as evidence of increased numbers or hypertrophy of glial fibrillary acidic protein (GFAP) positive astrocytes and ionized calcium binding adaptor molecule-1 (IBA-1) positive activated microglia. In an attempt to further understand the molecular effects of *Wwox* deletion in hippocampus we also performed RNA sequencing (RNA-Seq) analyses to compare the transcriptome profile of neural stem cell neurospheres generated from hippocampi of *Wwox KO* vs. *WT* mice.

2. Material and methods

2.1. Animal experiments

The protocol for the generation of full *Wwox KO* mice has been previously described by our group (Ludes-Meyers et al., 2009; Mallaret et al., 2014). Briefly, we crossed male *Wwox flox/wt* mice with female *BK5-Cre + Wwox flox/wt* mice (both in mixed 129SV/C57Bl/6 background). As described by Ramirez et al. Cre recombinase in BK5-Cre female breeder mice is activated in late oocytes with Cre protein persisting in the embryo leading to constitutive recombination and producing full knockout progeny in embryos that are *flox/flox* (Ramirez et al., 2004). As controls we used *Cre+; Wwox wt/wt* littermates (referred to as *Wwox WT* elsewhere in the text). *Wwox KO* mice (2 weeks old) and age-matched *WT* controls were used for comparative analysis. Mice from both sexes approximately 50% male, 50% female were used for all studies. All animals were bred and kept in a clean, modified-barrier animal facility, fed regular commercial mouse diet (Harlan Lab., Indianapolis, IN) under controlled light (12 L:12D) and temperature (20–24 °C). All animal research was conducted in facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) at the University of Texas, MD Anderson Cancer Center, Science Park, following international guidelines and all research was approved by the corresponding Institutional Animal Care and Use Committee (IACUC).

2.2. Animal perfusion and tissue processing

Wwox KO and *WT* mice were subjected to terminal anesthesia with isoflurane and trans-cardiac perfusion with 4% paraformaldehyde solution in phosphate buffer (PB). Following

this, the brain was carefully removed from the skull of each animal and post-fixed in 4% paraformaldehyde for ~16 h at 4 °C. The brain tissues were next treated with 30% sucrose solution in PB until it sank to the bottom and thirty-micrometer thick cryostat sections were cut coronally through the entire septo-temporal axis of the hippocampus. The sections were collected serially in 24-well plates filled with PBS. Every 20th section through the entire hippocampus was then selected from *Wwox KO* and *WT* mice and processed for immunohistochemistry, utilizing various antibodies for specific cell identification as described below.

2.3. Immunohistochemistry

Several sets of serial sections (every 15th or 20th) through the entire hippocampus were selected and processed for immunohistochemistry. The procedures used for immunostaining have been previously described (Mishra et al., 2015). Briefly, the sections were etched with PBS solution containing 20% methanol and 3% hydrogen peroxide for 20 min, rinsed thrice in PBS solution, and treated for 30 min in PBS solution containing 0.1% Triton-X 100 and an appropriate serum (10%) selected on the basis of the species in which the chosen secondary antibody was raised. The primary antibodies comprised anti-PV (P3088; Sigma-Aldrich), anti-NPY (T-4070; Peninsula Laboratories), anti-IBA-1 (ab5076; Abcam), or anti-GFAP (MAB360; Millipore). After an overnight incubation with the respective primary antibody solution, sections were washed thrice in PBS solution and incubated in an appropriate secondary antibody solution for 1 h. Biotinylated anti-rabbit (BA-1000; Vector Lab) and biotinylated anti-mouse (BA-2000; Vector Lab) were used as secondary antibodies in this study. The sections were washed thrice in PBS solution and treated with avidin-biotin complex reagent (PK-6100; Vector Lab) for 1 h. Peroxidase reaction was developed by using diaminobenzidine (SK-4100; Vector Lab) or vector SG (SK-4700; Vector Lab) as chromogens, and the sections were mounted on gelatin-coated slides, dehydrated, cleared, and cover slipped with Permount.

2.4. Stereological counting of PV+ and NPY+ GABA-ergic Interneurons

Numbers of PV+ or NPY+ interneurons were stereologically counted for the DG, CA1 and CA3 subfields of the hippocampus. All counts utilized every 15th or 20th section through the entire septo-temporal axis of the hippocampus and the optical fractionator method available in the StereoInvestigator system (Microbrightfield Inc.). The StereoInvestigator system consisted of a color digital video camera (Optronics Inc.) interfaced with a Nikon E600 microscope. A detailed protocol employed for cell counting using the optical fractionator has been previously described (Megahed et al., 2014).

2.5. Image analyses of IBA-1+, and GFAP+ immunoreactive structures in the hippocampus

The areas occupied by IBA-1+ microglia and GFAP+ astrocyte elements (area fractions) were measured per unit area of the tissue in the DG, CA1, and CA3 subfields of the hippocampus using Image J, as detailed in our previous reports (Kodali et al., 2015). In brief, images from the chosen subfields of the hippocampus were first digitized using 20× lens in a Nikon microscope outfitted with a digital video camera fixed to a computer and then saved in gray scale as a bitmap file. Using Image J, a binary image was created from

each picture by opting a threshold that retained all IBA-1+ or GFAP+ immunopositive structures but no background. The area occupied by the IBA-1+ or GFAP+ structures (*i.e.*, area fraction) in the binary image was quantified by selecting the Analyze command in the program. Area fraction of IBA-1+ or GFAP+ immunoreactive elements was calculated separately for DG, CA1, and CA3 subfields in each animal by using data from all chosen serial sections.

2.6. Statistical analysis

All the analysis (*Wwox KO vs. WT*) of the various cell subtypes was performed using statistical software GraphPad PRISM 7. Student's two-tailed unpaired *t*-test was used to compare interneurons numbers and additional biomarkers. *P* values of < 0.05 were considered significant.

2.7. Immunoblot analysis

Total protein extracts were prepared from mice hippocampi. Protein isolation was done using RIPA buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl₂, 100 mM NaF, 1 mM Na₃VO₄, 1 mM EGTA, 1% Triton X-100, 10% Glycerol) with protease inhibitor cocktail (Roche). For western blotting, 20 µg of total protein were separated on 10% SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked and antibodies were diluted in 5% dry milk/TBST. Primary antibodies used were: Gad65/67 (Millipore) 1:500 dilution, *Wwox* (using affinitypurified anti-WWOX rabbit polyclonal primary antibodies developed in our laboratory) 1:1000 dilution, HRP conjugated secondary antibodies were used followed by chemiluminescence (GE Healthcare). Actin was used as the protein loading control, and it was detected using monoclonal anti-actin antibody (Sigma) 1:5000 dilution and HRP conjugated anti-mouse secondary antibody 1:5000 dilution.

2.8. Generation of neurospheres

The detailed procedure for neural stem cells neurospheres generation and propagation is described elsewhere (Guo et al., 2012). Briefly, after euthanizing newborn *Wwox KO* or *WT* mice, the brain was collected in 20 ml cold HBSS (Hank's Balanced Salt Solution; Invitrogen/Gibco) in a sterile petri dish. Hippocampus was dissected from the brain and carefully chopped into smaller pieces. Next, 1 ml Trypsin (0.5%) (SIGMA) was added, and tissue was incubated for 10–15 min at 37 °C to dissociate the cells. To remove undissipated tissue particles, the cell suspension was filtered through 70 µm strainer and centrifuged for 5 min at 3000 rpm. Cell pellet was suspended in neurobasal medium (NBM, Thermo Fisher Scientific) containing 20 ng/ml EGF, 10 ng/ml FGF, 2 mM glutamine, antibiotics (100 units/ml penicillin and 100 g/ml streptomycin), and 0.125 µg/ml fungizone, plated in 6-well plates and maintained at an atmosphere of 5% CO₂ at 37 °C. After 4–7 days of incubation, neural stem cell formed neurospheres. Subcultures were prepared every 4–5 days by centrifugation of the neurospheres and dissociation of cells in trypsin; single-cell suspensions were re-plated in new culture dishes in fresh medium to obtain new neurospheres.

2.9. RNA-Seq and data analysis

RNA was isolated from neural stem cell neurospheres generated from *Wwox KO* and *WT* mouse hippocampi. To this end, we used TRIzol reagent (Invitrogen) and the RNeasy mini kit (Qiagen). RNA concentration and integrity were measured on an Agilent 2100 Bioanalyzer (Agilent Technologies). Only RNA samples with RNA integrity values (RIN) over 8.0 were considered for subsequent analysis. mRNA samples were processed for directional mRNA-seq library construction using the ScriptSeq v2 RNA-Seq Library Preparation Kit (Epicentre) according to the manufacturer's protocol. We performed 76 nt paired-end sequencing using an Illumina HiSeq3000 platform and obtained ~40 million tags per sample. The short-sequenced reads were mapped to the mouse reference genome (mm10) by the splice junction aligner TopHat V2.0.10. We employed several R/Bioconductor packages to calculate gene expression abundance at the whole-genome level using the aligned records (BAM files) and to identify differentially expressed genes between *Wwox KO* and *WT* neurospheres. Briefly, to identify differentially expressed genes between *Wwox KO* and *WT* samples we computed fold change using the EdgeR Bioconductor package based on the normalized log₂ based count per million values (Robinson et al., 2010). Data integration and visualization of differentially expressed transcripts between *Wwox KO* and *WT* mouse hippocampus derived neurospheres (log₂ fold change [log₂ FC] > ± 1, *p*-value < .005, false discovery rate [FDR] < 0.05) was done with the Multiexperiment Viewer Software. Functional enrichment analysis of dysregulated transcripts was performed using the Ingenuity Pathway Analysis (IPA) database (<http://www.ingenuity.com/index.html>).

2.10. Quantitative RT-PCR (qRT-PCR)

Total RNA from neurospheres was isolated as described above. Hippocampal tissue RNA was isolated using TRIzol reagent (Invitrogen) following manufacturer's instructions. RNA was quantified, and cDNA was prepared using RevertAid First Strand cDNA Synthesis Kit (ThermoFisher, Scientific) following manufacturer's instructions. The relative expression level for specific genes was determined in triplicate by qRT-PCR using the SYBR Green-based method. After normalization to *Gapdh* expression, the average fold change between *Wwox KO* and *WT* samples was calculated using the $2^{-(Ct)}$ method described elsewhere (Livak and Schmittgen, 2001). Student's two-tailed unpaired *t*-test was used to compare gene expression values, *p*-values of < 0.05 were considered significant. Primer sequences of the genes tested by qRT-PCR are shown in Supplementary Table 1.

3. Results

3.1. *Wwox KO* mice hippocampi exhibit a decrease in PV+ and NPY+ inhibitory interneurons

Inhibitory signals from various subpopulations of GABA-ergic interneurons to principal neurons are critical to maintain the stability of the neuronal circuitry. The loss of GABA-ergic interneurons alters the balance of excitatory and inhibitory synaptic transmission inducing hippocampal hyperexcitability potentially leading to epileptiform activity and affecting cognitive functions (Liu et al., 2014). We first examined the distribution of fast-spiking parvalbumin expressing (PV+) GABA-ergic interneurons in the DG (dentate gyrus)

and the CA1 and CA3 (cornu ammonis) hippocampal subfields of *Wwox KO* ($n = 7$) and *WT* ($n = 7$) mice. To this end, we used immunohistochemical staining of coronal brain sections with an antibody against PV followed by stereological quantification (Fig. 1). In the DG region of *Wwox WT* mice, PV+ interneurons were clearly observed (Fig. 1 A1). In contrast, the DG region of *Wwox KO* mice displayed a significant reduction in number of PV+ interneurons. Some hippocampal areas in *Wwox KO* mice showed a complete absence of such cells (Fig. 1 B1). A significantly low number of PV+ interneurons in *Wwox KO* mice was also evident in the CA1 and CA3 subfields (Figs. 1 A2–A3, B2–B3, and C2–C3). Stereological quantification indicated that *Wwox KO* mice displayed a statistically significant reduction in the total number of PV+ interneurons in the DG region ($p < .005$, Fig. 1 C1) and CA1 subfield ($p < .05$, Figs. 1 C2), in comparison to control mice. The overall reduction of PV+ interneurons in *Wwox KO* mice amounted to 44% when the hippocampus was taken in its entirety ($p < .005$, Fig. 1 D).

We also analyzed the abundance of a second subpopulation of GABA-ergic interneurons, the NPY+ interneurons. The neuropeptide Y released from NPY+ GABA-ergic interneurons is an endogenous anticonvulsant neurotransmitter that modulates the activity of excitatory neurons (Vezzani et al., 1999). We calculated the abundance of these interneurons in hippocampal subfields of *Wwox KO* ($n = 6$) and *WT* ($n = 6$) mice by immunostaining of coronal brain sections using a NPY antibody followed by stereological analysis (Fig. 2). In the DG region of *WT* mice, significant numbers of NPY+ cells were clearly observed, especially in the dentate hilus region (Fig. 2 A1), in contrast the DG region of *Wwox KO* mice displayed a 30% reduction in the total number of NPY+ interneurons when compared to control *WT* mice ($p < .05$) (Figs. 2 B1 and C1). However, the CA1 and CA3 subfields, did not exhibit any obvious difference in the number of NPY+ interneurons between *Wwox KO* and *WT* mice (Figs. 2 A2–A3, B2–B3, and C2–C3). Number of NPY+ interneurons in the entire hippocampus is shown in Fig. 2 D.

In summary, *Wwox KO* mice exhibit significant reductions in the abundance of both PV+ and NPY+ GABA-ergic interneurons in the various hippocampal subfields.

3.2. *Wwox KO* mice hippocampi display evidence of microgliosis

Pathogenic insults to the CNS generate a non-specific reactive response affecting glial cells termed gliosis (Burda and Sofroniew, 2014). Gliosis involves hypertrophy and activation of different types of glial cells including microglia and astrocytes and is often the result of a reactive inflammatory response (Devinsky et al., 2013). Microgliosis (activation of microglia) is commonly the first observed stage of gliosis. We investigated microglia activation by immunohistochemical staining for ionized calcium binding adaptor molecule-1 (IBA-1), also known as allograft inflammatory factor expressed in activated macrophages, both in *WT* ($n = 6$) and *Wwox KO* ($n = 6$) mice (Fig. 3). The area fraction (AF) occupied by IBA-1+ cells was marginally higher in the DG region (Figs. 3 A1, B1 and C1), however the CA1 and CA3 subfields displayed a significant increase ($p < .05$) in the AF occupied by IBA-1+ structures in *Wwox KO* mice and when the hippocampus ($p < .005$) is considered in its entirety (Figs. 3 A2–A3, B2–B3, C2–C3, and D). Importantly, IBA-1+ cells in CA1 and

CA3 subfields of *Wwox KO* were less ramified, displayed shorter and thicker processes and larger soma, characteristic of activated microglia (see Figs. 3 B2–B3 insets).

3.3. *Wwox KO* mice hippocampi display evidence of astrogliosis and increased inflammatory cytokines expression

We also investigated for evidence of astrogliosis (activation of astrocytes) by means of glial fibrillary acidic protein (GFAP) immunostaining and area fraction analysis using Image J. We observed a significant increase in the area occupied by astrocytic elements in hippocampi from *Wwox KO* mice ($n = 8$) in comparison to *WT* mice ($n = 6$) (Fig. 4). Astrocytes displayed hypertrophy as well as hyperplasia in the hippocampus of *Wwox KO* mice. As a consequence, in *Wwox KO* mice, the area fraction (AF) occupied by GFAP+ soma and processes of astrocytes in the CA1 and CA3 subfields displayed a very significant increase of 36% and 53%, respectively ($p < .05$ Figs. 4 A2–A3, B2–B3, and C2–C3), whereas in the DG region the increment was marginal (Figs. 4 A1, B1 and C1). When the hippocampus was taken in its entirety, the overall increase in GFAP+ structures was 30% in *Wwox KO* mice ($p < .05$, Fig. 4 D).

Since we observed evidence of neuroinflammation in the form of activated microglia and reactive astrocytes in *Wwox KO* mice, we further investigated the expression of well known neuroinflammatory cytokines *Il6* and *Tnf-a* in hippocampal tissue by qRT-PCR. We observed > 1.5 fold upregulation of both cytokines (*Il6* significant at $p < .05$) in *Wwox KO* ($n = 4$) mice in comparison to *Wwox WT* ($n = 4$) mice (Fig. 4 E).

3.4. *Wwox KO* mice hippocampi show reduced GAD65/67 protein expression

GABA, the major inhibitory neurotransmitter in the mammalian brain, is synthesized by two glutamate decarboxylase isoforms, GAD65 and GAD67. GAD65/67 protein expression was shown to accurately reflect levels of GABA synthesis and abundance (Lindfors, 1993), therefore decreased expression of these proteins would also indicate lower GABA levels. As observed in Fig. 5A, Western blot analysis of hippocampal protein extracts obtained from *Wwox KO* mice ($n = 5$) compared with *WT* mice ($n = 5$) revealed significantly lower levels of GAD65/67 protein expression. Quantitative densitometry analysis demonstrates a significant reduction in GAD65/67 expression in *Wwox KO* mice ($p < .05$, Fig. 5B).

3.5. Comparative transcriptome profiling of hippocampus derived neural stem cell neurospheres

To gain some insight on the molecular effects of *Wwox* deletion, we performed RNA-Seq analyses for comparing the gene expression profiles of neural stem cell (NSC) neurospheres generated from hippocampi of *Wwox KO* and *WT* mice. Neurospheres are an excellent model system for the study of NSCs *in vitro* (Guo et al., 2012). Our aim for performing transcriptome profiling on RNA isolated from neurospheres is to determine the effect of *Wwox* deletion in comparable pure populations of progenitor cells capable of differentiating into diverse CNS cell subtypes while avoiding the confounding factors of tissue heterogeneity that would arise from analyzing total hippocampus RNA.

Unsupervised analysis of RNA-Seq data demonstrates clear segregation of *Wwox KO* and *WT* control mice samples (Fig. 6 A). Comparative transcriptome analysis allowed us to identify 283 differentially expressed genes between both groups ($\log_2 \text{FC} > \pm 1$, p value $< .005$, $\text{FDR} < 0.05$) (Fig. 6 A). Out of the 283 differentially expressed genes, 184 transcripts were up-regulated and 99 were down-regulated in *Wwox KO* samples when compared with control samples (Supplementary Table 2). Next, we performed functional enrichment analysis using the Ingenuity Pathway Analysis (IPA) platform. Interestingly, based on the behavior of dysregulated transcripts in the *Wwox KO* group, IPA identified ‘neurological disease’ among the top diseases (p -value range: $7.10\text{E-}05 - 7.74\text{E-}20$) and ‘nervous system development and function’ as the top physiological biofunction (p -value range: $6.82\text{E-}05 - 9.06\text{E-}26$). Within the neurological disease subgroup, ‘epilepsy’, ‘seizure disorder’, ‘cognitive impairment’ and ‘neurodegeneration’ showed a positive Z score value implying that these disorders are positively associated with *Wwox* deletion (Fig. 6 B).

Next, from the list of 283 differentially expressed genes we identified a group of transcripts on the basis of either one of the following two criteria: (i) the transcript falls within a panel of 172 genes implicated in epilepsy as reported by Rim et al.; this dataset is based on an extensive literature review and the Online Mendelian Inheritance in Man (OMIM) database search (Rim et al., 2018), or (ii) the gene is identified by IPA as a member of the set of dysregulated genes that identify with epilepsy and/or seizure related disorders as per functional enrichment analyses. Table 1 shows the list of 16 genes that were short-listed based on the described criteria. Also shown in Table 1 is the function and potential relevance of these genes with epilepsy supported by available literature (Table 1). All these RNA-Seq observations were validated by qRT-PCR on RNA isolated from neurospheres (data not shown).

To further investigate whether any of the gene expression changes observed affecting progenitor cells *in vitro* would be observable *in vivo*, we analyzed expression of all genes on RNA isolated from hippocampi freshly dissected from a separate set of *Wwox KO* ($n = 4$) and *WT* ($n = 4$) mice. From this *in vitro - in vivo* comparison the most striking changes behaving in the same direction in both conditions was the very significant downregulation in expression of the NMDA receptor *Grin2c*, glutamate receptor *Grm3*, and voltage-gated potassium channel *Kcna2* genes in *Wwox KO* mice when compared to *WT* controls (Figs. 6 C and D).

4. Discussion

This study provides the first pathophysiological evidence on the effects of *Wwox* loss of function in the brain. Importantly, we observed that *Wwox* deletion leads to a significant reduction in the overall number of PV+ and NPY+ GABA-ergic inhibitory interneurons in mouse hippocampus. Additionally, we also detected evidence of active neuroinflammation and gliosis in the brains of *Wwox KO* mice.

Loss of GABA-ergic inhibitory function have been observed in several human epileptiform disorders and experimental animal models of epilepsy and is postulated to be a susceptibility factor or trigger of some genetic forms of human epilepsy (Powell, 2013). Genetic mutations

2010). Notably, pro-inflammatory molecules, microgliosis, astrogliosis, and other indicators of inflammation have been found in the resected hippocampi of patients with different forms of epilepsy and also in rodent models of epilepsy (Shapiro et al., 2008; Vezzani et al., 2011). The finding of biomarkers of neuroinflammation in *Wwox KO* mice brains supports the idea that inflammation might play a role in *Wwox* related epilepsy. However, further investigation is needed to gather additional mechanistic insight on what is cause or consequence upon *Wwox* loss of function.

We also performed RNA-Seq to profile the transcriptome wide effects of *Wwox* deletion in neural progenitor cells. Interestingly, the comparative analysis of transcriptional profiles from NSC derived from *Wwox KO* vs. *WT* mice revealed significant differences reflecting alterations that identify with CNS related disorders and in particular ‘cognitive impairment’, ‘seizures’, ‘seizure disorders’ and ‘epilepsy’ among the most prevalent functional annotations. Importantly, this is in close agreement with human familial syndromes associated with *WWOX* mutations and loss of function. At the specific gene level, we observed a significant down-regulation of *Glutamate Ionotropic Receptor NMDA Subunit 2C (Grin2c)*, *Glutamate Metabotropic Receptor 3 (Grm3)*, and *Potassium Voltage-Gated Channel Subfamily A Member 2 (Kcna2)* in *Wwox KO* NSCs as well as in whole hippocampal tissue.

GRIN2C is a subunit of the glutamate-gated ion channels *N*-methyl-D-aspartate receptors (NMDAR). NMDARs are crucial for neuronal communication and are capable of converting specific patterns of neuronal activity into long-term changes in synapse structure and function. Dysfunction of NMDARs including GRIN2A and GRIN2B has been reported in various neurological and psychiatric disorders (Paoletti et al., 2013). Interestingly, GRIN2A loss of function mutations, either through nonsense-mediated mRNA decay or premature termination resulting in the synthesis of dysfunctional protein, have been associated with focal epilepsy and speech disorder with or without mental retardation (Endele et al., 2010). In line, GRIN2B loss of function mutations have been associated with mental retardation and autism (Endele et al., 2010), while in cases of early infantile epileptic encephalopathy both loss and gain of GRIN2B function mutations have been reported (Platzer et al., 2017). Therefore, it is logical to speculate that *Grin2C* downregulation may also lead to abnormal NMDAR receptor function by altering receptor subunit composition and indeed this has been speculated to be a key variable and potential cause of epileptogenesis (Paoletti et al., 2013).

KCNA2 is a member of voltage-gated potassium channel family that are expressed in the CNS and plays an important role in neuronal excitability and neurotransmitter release (Lai and Jan, 2006). Many *de novo* missense and loss- or gain-of-function mutations in *KCNA2* have been associated with severe early-onset epileptic encephalopathy, ataxia, cognitive and language impairment, and behavioral disorders (Masnada et al., 2017). In most of the cases, the onset of epilepsy occurred within the first to second year of life, while the loss- and gain-of-function subgroups show the earliest, often neonatal onset. Mice harboring *Kcna2* mutations are also reported to display chronic motor incoordination, ataxia, increased seizure, and premature death due to loss of *Kcna2* function (Xie et al., 2010). Early-onset epilepsy and premature death observed in *KCNA2* mutant humans and mice are similar

phenotypes to those observed in our *Wwox KO* mouse model which makes *Kcna2* an important candidate for future studies.

We also observed a decrease in *Grm3* expression in *Wwox KO* mice. *Grm3* is a G protein-coupled metabotropic glutamate receptor and acts in part as an inhibitory autoreceptor, influencing synaptic plasticity (Niswender and Conn, 2010). A role of this receptor has been associated with the pathophysiology and therapy of many neuropsychiatric disorders including bipolar disorders, Alzheimer's disease, anxiety disorders and in particular schizophrenia (Moreno et al., 2009). A potential role for metabotropic glutamate receptors has also been suggested in epilepsy (Aronica et al., 2000).

In conclusion, our observations may explain, at least in part, what is occurring in the brains of patients affected by WWOX loss of function pathologies. One notable observation regarding WWOX related epileptic disorders is that cases characterized by complete WWOX loss of function mutations, as in early infantile epileptic encephalopathies (EIEE28, OMIM #616211) also described as WOREE syndrome, are always accompanied by mental retardation, usually display severe brain structural abnormalities, and patients die within the first two years of life (Abdel-Salam et al., 2014; Ben-Salem et al., 2015; Mignot et al., 2015; Tabarki et al., 2015; Valduga et al., 2015), thus displaying a very short lifespan similar to our mouse *Wwox KO* model where all mice die by approximately 3 weeks of age (Ludes-Meyers et al., 2009). However, in other cases presented with missense mutations that lead to expression of a defective WWOX protein (*i.e.* hypomorphs) premature death was not reported (Mallaret et al., 2014; Mignot et al., 2015). In addition to epilepsy and seizure disorders, alterations affecting WWOX have also been associated with other neuropathologies including Alzheimer's disease (Sze et al., 2004; Wang et al., 2012), autism (Bartnik et al., 2012; Leppa et al., 2016) and other intellectual disabilities (Alkhateeb et al., 2016) and interestingly the WWOX locus was also found associated to infant brain volumes (Xia et al., 2017).

Importantly, in recent studies, *Wwox* has been identified as one of a very limited set of long neural genes characterized by harboring recurrent double strand break clusters and undergoing genomic rearrangements in primary neural stem/progenitor cells as part of critical processes likely associated with the specialized behavior of brain cells (Wei et al., 2016). Strikingly, most of these genes have been associated to CNS pathologies and cancer (Wei et al., 2016). These observations further stress the critical relevance of WWOX in normal CNS development.

The observations reported here fill a gap of knowledge providing clues to start understanding the consequences and potential mechanisms at play in the CNS of patients affected by WWOX loss of function conditions. Although these human pathologies are rare, it stimulates to further pursue studies aimed at understanding the clearly important role of WWOX in normal CNS development and function.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by CPRIT Core Facility Support Grant (RP120348); The Virginia Harris Cockrell Foundation to C.M.A. and The Department of Defense (CDMPRP Grant) and Department of Veterans Affairs (Merit Award) to A.K.S. We want to thank The University of Texas MD Anderson Cancer Center Animal Support Facility in Smithville (P30 NIH CA16672) for providing necessary infrastructure and facilities for conducting this work. The authors are also grateful to Yue Lu and Kevin Lin for bioinformatic support.

Abbreviations:

WVOX	WW domain containing oxidoreductase
EIEE	Early infantile epileptic encephalopathy
PV	Parvalbumin
NPY	Neuropeptide Y
GAD65/67	Glutamic Acid Decarboxylase protein isoforms
GABA	γ -aminobutyric acid
WOREE	WVOX-related epileptic encephalopathy
IBA-1	Ionized calcium binding adaptor molecule-1-positive
GFAP	Glial fibrillary acidic protein
DG	Dentate gyrus
DH	Dentate hilus
CA1 and CA3	Cornu ammonis subfields
GCL	Granule cell layer
GRIN2C	Glutamate Ionotropic Receptor NMDA Subunit 2C
GRM3	Glutamate Metabotropic Receptor 3
KCNA2	Potassium Voltage-Gated Channel Subfamily A Member 2

References

- Abdel-Salam G, Thoenes M, Afifi HH, Korber F, Swan D, Bolz HJ, 2014 The supposed tumor suppressor gene WVOX is mutated in an early lethal microcephaly syndrome with epilepsy, growth retardation and retinal degeneration. *Orphanet J Rare Dis* 9, 12. [PubMed: 24456803]
- Aldaz CM, Ferguson BW, Abba MC, 2014 WVOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. *Biochim. Biophys. Acta* 1846, 188–200. [PubMed: 24932569]
- Alkhateeb AM, Aburahma SK, Habbab W, Thompson IR, 2016 Novel mutations in WVOX, RARS2, and C10orf2 genes in consanguineous Arab families with intellectual disability. *Metab. Brain Dis* 31, 901–907. [PubMed: 27121845]
- Angeloni D, Lindor NM, Pack S, Latif F, Wei MH, Lerman MI, 1999 CALL gene is haploinsufficient in a 3p- syndrome patient. *Am. J. Med. Genet* 86, 482–485. [PubMed: 10508992]

- Aronica E, van Vliet EA, Mayboroda OA, Troost D, da Silva FH, Gorter JA, 2000 Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. *Eur. J. Neurosci* 12, 2333–2344. [PubMed: 10947812]
- Bartnik M, et al., 2012 Application of array comparative genomic hybridization in 102 patients with epilepsy and additional neurodevelopmental disorders. *Am. J. Med. Genet. B Neuropsychiatr. Genet* 159B, 760–771. [PubMed: 22825934]
- Bednarek AK, Lafflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM, 2000 WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. *Cancer Res.* 60, 2140–2145. [PubMed: 10786676]
- Ben-Salem S, Al-Shamsi AM, John A, Ali BR, Al-Gazali L, 2015 A novel whole exon deletion in WWOX gene causes early epilepsy, intellectual disability and optic atrophy. *J. Mol. Neurosci* 56, 17–23. [PubMed: 25403906]
- Burda JE, Sofroniew MV, 2014 Reactive gliosis and the multicellular response to CNS damage and disease. *Neuron* 81, 229–248. [PubMed: 24462092]
- Busch RM, Lineweaver TT, Naugle RI, Kim KH, Gong Y, Tilelli CQ, Prayson RA, Bingaman W, Najm IM, Diaz-Arrastia R, 2007 ApoE-epsilon4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. *Neurology* 68, 409–414. [PubMed: 17283313]
- Chang HT, Liu CC, Chen ST, Yap YV, Chang NS, Sze CI, 2014 WW domain-containing oxidoreductase in neuronal injury and neurological diseases. *Oncotarget* 5, 11792–11799. [PubMed: 25537520]
- Chen ST, Chuang JI, Wang JP, Tsai MS, Li H, Chang NS, 2004 Expression of WW domain-containing oxidoreductase WOX1 in the developing murine nervous system. *Neuroscience* 124, 831–839. [PubMed: 15026124]
- Colmers WF, Bleakman D, 1994 Effects of neuropeptide Y on the electrical properties of neurons. *Trends Neurosci.* 17, 373–379. [PubMed: 7529442]
- Corbett MA, Bellows ST, Li M, Carroll R, Micallef S, Carvill GL, Myers CT, Howell KB, Maljevic S, Lerche H, Gazina EV, Mefford HC, Bahlo M, Berkovic SF, Petrou S, Scheffer IE, Gecz J, 2016 Dominant KCNA2 mutation causes episodic ataxia and pharmacoresponsive epilepsy. *Neurology* 87, 1975–1984. [PubMed: 27733563]
- Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA, 2013 Glia and epilepsy: excitability and inflammation. *Trends Neurosci.* 36, 174–184. [PubMed: 23298414]
- Elsaadany L, El-Said M, Ali R, Kamel H, Ben-Omran T, 2016 W44X mutation in the WWOX gene causes intractable seizures and developmental delay: a case report. *BMC Med. Genet* 17, 53. [PubMed: 27495153]
- Endele S, et al., 2010 Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. *Nat. Genet* 42, 1021–1026. [PubMed: 20890276]
- Erickson JC, Clegg KE, Palmiter RD, 1996 Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. *Nature* 381, 415–421. [PubMed: 8632796]
- Freudenthal B, Kulaveerasingam D, Lingappa L, Shah MA, Brueton L, Wassmer E, Ognjanovic M, Dorison N, Reichold M, Bockenhauer D, Kleta R, Zdebik AA, 2011 KCNJ10 mutations disrupt function in patients with EAST syndrome. *Nephron Physiol.* 119, 40–48.
- Frints SG, Marynen P, Hartmann D, Fryns JP, Steyaert J, Schachner M, Rolf B, Craessaerts K, Snellinx A, Hollanders K, D'Hooge R, De Deyn PP, Froyen G, 2003 CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. *Hum. Mol. Genet* 12, 1463–1474. [PubMed: 12812975]
- Fu LY, van den Pol AN, 2007 GABA excitation in mouse hilar neuropeptide Y neurons. *J. Physiol* 579, 445–464. [PubMed: 17204505]
- Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH, 2010 Mechanisms underlying inflammation in neurodegeneration. *Cell* 140, 918–934. [PubMed: 20303880]
- Gribaa M, Salih M, Anheim M, Lagier-Tourenne C, H'Mida D, Drouot N, Mohamed A, Elmalik S, Kabiraj M, Al-Rayess M, Almubarak M, Betard C, Goebel H, Koenig M, 2007 A new form of childhood onset, autosomal recessive spinocerebellar ataxia and epilepsy is localized at 16q21-q23. *Brain* 130, 1921–1928. [PubMed: 17470496]


- Gronskov K, Hjalgrim H, Nielsen IM, Brondum-Nielsen K, 2004 Screening of the ARX gene in 682 retarded males. *Eur. J. Hum. Genet* 12, 701–705. [PubMed: 15199382]
- Guo W, Patzlaff NE, Jobe EM, Zhao X, 2012 Isolation of multipotent neural stem or progenitor cells from both the dentate gyrus and subventricular zone of a single adult mouse. *Nat. Protoc* 7, 2005–2012. [PubMed: 23080272]
- Han HA, Cortez MA, Snead OC, 2012 GABAB Receptor and Absence Epilepsy. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (Eds.), *Jasper's Basic Mechanisms of the Epilepsies* Bethesda, MD.
- Hundallah K, Alenizi A, AlHashem A, Tabarki B, 2016 Severe early-onset epileptic encephalopathy due to mutations in the KCNA2 gene: Expansion of the genotypic and phenotypic spectrum. *Eur. J. Paediatr. Neurol* 20, 657–660. [PubMed: 27117551]
- Hung CC, Chen PL, Huang WM, Tai JJ, Hsieh TJ, Ding ST, Hsieh YW, Liou HH, 2013 Gene-wide tagging study of the effects of common genetic polymorphisms in the alpha subunits of the GABA(A) receptor on epilepsy treatment response. *Pharmacogenomics* 14 (203), 1849–1856. [PubMed: 24236484]
- Jurkat-Rott K, Freilinger T, Dreier JP, Herzog J, Gobel H, Petzold GC, Montagna P, Gasser T, Lehmann-Horn F, Dichgans M, 2004 Variability of familial hemiplegic migraine with novel A1A2 Na⁺/K⁺-ATPase variants. *Neurology* 62, 1857–1861. [PubMed: 15159495]
- Karlsson G, Kolb C, Hausdorf A, Portet C, Schmutz M, Olpe HR, 1992 GABAB receptors in various in vitro and in vivo models of epilepsy: a study with the GABAB receptor blocker CGP 35348. *Neuroscience* 47, 63–68. [PubMed: 1315938]
- Kash SF, Johnson RS, Tecott LH, Noebels JL, Mayfield RD, Hanahan D, Baekkeskov S, 1997 Epilepsy in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. *Proc. Natl. Acad. Sci. U. S. A* 94, 14060–14065. [PubMed: 9391152]
- Klausberger T, Marton LF, O'Neill J, Huck JH, Dalezios Y, Fuentealba P, Suen WY, Papp E, Kaneko T, Watanabe M, Csicsvari J, Somogyi P, 2005 Complementary roles of cholecystokinin- and parvalbumin-expressing GABAergic neurons in hippocampal network oscillations. *J. Neurosci* 25, 9782–9793. [PubMed: 16237182]
- Kobayashi M, Buckmaster PS, 2003 Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. *J. Neurosci* 23, 2440–2452. [PubMed: 12657704]
- Kodali M, Parihar VK, Hattiangady B, Mishra V, Shuai B, Shetty AK, 2015 Resveratrol prevents age-related memory and mood dysfunction with increased hippocampal neurogenesis and microvasculature, and reduced glial activation. *Sci. Rep* 5, 8075. [PubMed: 25627672]
- Lai HC, Jan LY, 2006 The distribution and targeting of neuronal voltage-gated ion channels. *Nat. Rev. Neurosci* 7, 548–562. [PubMed: 16791144]
- Lemke JR, Hendrickx R, Geider K, Laube B, Schwake M, Harvey RJ, James VM, Pepler A, Steiner I, Hortnagel K, Neidhardt J, Ruf S, Wolff M, Bartholdi D, Caraballo R, Platzer K, Suls A, De Jonghe P, Biskup S, Weckhuysen S, 2014 GRIN2B mutations in West syndrome and intellectual disability with focal epilepsy. *Ann. Neurol* 75, 147–154. [PubMed: 24272827]
- Leppa VM, Kravitz SN, Martin CL, Andrieux J, Le Caignec C, Martin-Coignard D, Dybuncio C, Sanders SJ, Lowe JK, Cantor RM, Geschwind DH, 2016 Rare Inherited and De Novo CNVs Reveal complex Contributions to ASD Risk in Multiplex families. *Am. J. Hum. Genet* 99, 540–554. [PubMed: 27569545]
- Lerche H, Weber YG, Baier H, Jurkat-Rott K, Kraus de Camargo O, Ludolph AC, Bode H, Lehmann-Horn F, 2001 Generalized epilepsy with febrile seizures plus: further heterogeneity in a large family. *Neurology* 57, 1191–1198. [PubMed: 11591834]
- Lindfors N, 1993 Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 17, 887–903.
- Liu YQ, Yu F, Liu WH, He XH, Peng BW, 2014 Dysfunction of hippocampal interneurons in epilepsy. *Neurosci. Bull* 30, 985–998. [PubMed: 25370443]
- Livak KJ, Schmittgen TD, 2001 Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25, 402–408. [PubMed: 11846609]

- Ludes-Meyers JH, Kil H, Parker-Thornburg J, Kusewitt DF, Bedford MT, Aldaz CM, 2009 Generation and characterization of mice carrying a conditional allele of the *Wwox* tumor suppressor gene. *PLoS One* 4, e7775. [PubMed: 19936220]
- Mallaret M, Synofzik M, Lee J, Sagum CA, Mahajnah M, Sharkia R, Drouot N, Renaud M, Klein FA, Anheim M, Tranchant C, Mignot C, Mandel JL, Bedford M, Bauer P, Salih MA, Schule R, Schols L, Aldaz CM, Koenig M, 2014 The tumour suppressor gene *WWOX* is mutated in autosomal recessive cerebellar ataxia with epilepsy and mental retardation. *Brain* 137, 411–419. [PubMed: 24369382]
- Masnada S, et al., 2017 Clinical spectrum and genotype-phenotype associations of *KCNA2*-related encephalopathies. *Brain* 140, 2337–2354. [PubMed: 29050392]
- Megahed T, Hattiangady B, Shuai B, Shetty AK, 2014 Parvalbumin and neuropeptide Y expressing hippocampal GABA-ergic inhibitory interneuron numbers decline in a model of Gulf War illness. *Front. Cell. Neurosci* 8, 447. [PubMed: 25620912]
- Meldrum BS, 1994 The role of glutamate in epilepsy and other CNS disorders. *Neurology* 44, S14–S23. [PubMed: 7970002]
- Mignot C, et al., 2015 *WWOX*-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation. *J. Med. Genet* 52, 61–70. [PubMed: 25411445]
- Mishra V, Shuai B, Kodali M, Shetty GA, Hattiangady B, Rao X, Shetty AK, 2015 Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with suppression of Oxidative stress and Inflammation. *Sci. Rep* 5, 17807. [PubMed: 26639668]
- Moreno JL, Sealfon SC, Gonzalez-Maeso J, 2009 Group II metabotropic glutamate receptors and schizophrenia. *Cell. Mol. Life Sci* 66, 3777–3785. [PubMed: 19707855]
- Niswender CM, Conn PJ, 2010 Metabotropic glutamate receptors: physiology, pharmacology, and disease. *Annu. Rev. Pharmacol. Toxicol* 50, 295–322. [PubMed: 20055706]
- Nunez MI, Ludes-Meyers J, Aldaz CM, 2006 *WWOX* protein expression in normal human tissues. *J. Mol. Histol* 37, 115–125. [PubMed: 16941225]
- Orenstein N, Goldberg-Stern H, Straussberg R, Bazak L, Weisz Hubshman M, Kropach N, Gilad O, Scheuerman O, Dory Y, Kraus D, Tzur S, Magal N, Kilim Y, Shkalam Zemer V, Basel-Salmon L, 2018 A de novo *GABRA2* missense mutation in severe early-onset epileptic encephalopathy with a choreiform movement disorder. *Eur. J. Paediatr. Neurol* 22, 516–524. [PubMed: 29422393]
- Paoletti P, Bellone C, Zhou Q, 2013 NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. *Nat. Rev. Neurosci* 14, 383–400. [PubMed: 23686171]
- Paradiso B, Zucchini S and Simonato M, Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements. *Front. Cell. Neurosci* 7, 2013, 152. [PubMed: 24062643]
- Pena SD, Coimbra RL, 2015 Ataxia and myoclonic epilepsy due to a heterozygous new mutation in *KCNA2*: proposal for a new channelopathy. *Clin. Genet* 87, e1–e3. [PubMed: 25477152]
- Platzer K, et al., 2017 *GRIN2B* encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. *J. Med. Genet* 54, 460–470. [PubMed: 28377535]
- Powell EM, 2013 Interneuron development and epilepsy: early genetic defects cause long-term consequences in seizures and susceptibility. *Epilepsy Curr* 13, 172–176. [PubMed: 24009481]
- Ramirez A, Page A, Gandarillas A, Zanet J, Pibre S, Vidal M, Tusell L, Genesca A, Whitaker DA, Melton DW, Jorcano JL, 2004 A keratin K5Cre transgenic line appropriate for tissue-specific or generalized Cre-mediated recombination. *Genesis* 39, 52–57. [PubMed: 15124227]
- Reichold M, Zdebik AA, Lieberer E, Rapedius M, Schmidt K, Bandulik S, Sterner C, Tegtmeyer I, Penton D, Baukrowitz T, Hulton SA, Witzgall R, Ben-Zeev B, Howie AJ, Kleta R, Bockenhauer D, Warth R, 2010 *KCNJ10* gene mutations causing EAST syndrome (epilepsy, ataxia, sensorineural deafness, and tubulopathy) disrupt channel function. *Proc. Natl. Acad. Sci. U. S. A* 107, 14490–14495. [PubMed: 20651251]
- Ried K, Finnis M, Hobson L, Mangelsdorf M, Dayan S, Nancarrow JK, Woollatt E, Kremmidiotis G, Gardner A, Venter D, Baker E, Richards RI, 2000 Common chromosomal fragile site *FRA16D* sequence: identification of the *FOR* gene spanning *FRA16D* and homozygous deletions and translocation breakpoints in cancer cells. *Hum. Mol. Genet* 9, 1651–1663. [PubMed: 10861292]
- Rim JH, Kim SH, Hwang IS, Kwon SS, Kim J, Kim HW, Cho MJ, Ko A, Youn SE, Kim J, Lee YM, Chung HJ, Lee JS, Kim HD, Choi JR, Lee ST, Kang HC, 2018 Efficient strategy for the molecular

diagnosis of intractable early-onset epilepsy using targeted gene sequencing. *BMC Med. Genet* 11, 6.

- Riva MA, Fumagalli F, Blom JM, Donati E, Racagni G, 1995 Adrenalectomy reduces FGF-1 and FGF-2 gene expression in specific rat brain regions and differently affects their induction by seizures. *Brain Res. Mol. Brain Res* 34, 190–196. [PubMed: 8750822]
- Robinson MD, McCarthy DJ, Smyth GK, 2010 edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140. [PubMed: 19910308]
- Sachdev M, Gainza-Lein M, Tchapyjnikov D, Jiang YH, Loddenkemper T, Mikati MA, 2017 Novel clinical manifestations in patients with KCNA2 mutations. *Seizure* 51, 74–76. [PubMed: 28806589]
- Sala-Rabanal M, Kucheryavykh LY, Skatchkov SN, Eaton MJ, Nichols CG, 2010 Molecular mechanisms of EAST/SeSAME syndrome mutations in Kir4.1 (KCNJ10). *J. Biol. Chem* 285, 36040–36048. [PubMed: 20807765]
- Scheffer IE, Wallace RH, Phillips FL, Hewson P, Reardon K, Parasivam G, Stromme P, Berkovic SF, Geicz J, Mulley JC, 2002 X-linked myoclonic epilepsy with spasticity and intellectual disability: mutation in the homeobox gene ARX. *Neurology* 59, 348–356. [PubMed: 12177367]
- Schrock MS, Batar B, Lee J, Druck T, Ferguson B, Cho JH, Akakpo K, Hagrass H, Heerema NA, Xia F, Parvin JD, Aldaz CM, Huebner K, 2017 Wwox-Bra1 interaction: role in DNA repair pathway choice. *Oncogene* 36, 2215–2227. [PubMed: 27869163]
- Schubert J, et al., 2014 Mutations in STX1B, encoding a presynaptic protein, cause fever-associated epilepsy syndromes. *Nat. Genet* 46, 1327–1332. [PubMed: 25362483]
- Schwaller B, Tetko IV, Tandon P, Silveira DC, Vreugdenhil M, Henzi T, Potier MC, Celio MR, Villa AE, 2004 Parvalbumin deficiency affects network properties resulting in increased susceptibility to epileptic seizures. *Mol. Cell. Neurosci* 25, 650–663. [PubMed: 15080894]
- Schwartzkroin PA, 1994 Role of the hippocampus in epilepsy. *Hippocampus* 4, 239–242. [PubMed: 7842043]
- Shapiro LA, Wang L, Ribak CE, 2008 Rapid astrocyte and microglial activation following pilocarpine-induced seizures in rats. *Epilepsia* 49 (Suppl. 2), 33–41.
- Srivastava S, Cohen J, Pevsner J, Aradhya S, McKnight D, Butler E, Johnston M, Fatemi A, 2014 A novel variant in GABRB2 associated with intellectual disability and epilepsy. *Am. J. Med. Genet. A* 164A, 2914–2921. [PubMed: 25124326]
- Stromme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, Bruyere H, Lutchera V, Gedeon AK, Wallace RH, Scheffer IE, Turner G, Partington M, Frints SG, Fryns JP, Sutherland GR, Mulley JC, Geicz J, 2002 Mutations in the human ortholog of *Aristaless* cause X-linked mental retardation and epilepsy. *Nat. Genet* 30, 441–445. [PubMed: 11889467]
- Suzuki H, Katayama K, Takenaka M, Amakasu K, Saito K, Suzuki K, 2009 A spontaneous mutation of the *Wwox* gene and audiogenic seizures in rats with lethal dwarfism and epilepsy. *Genes Brain Behav.* 8, 650–660. [PubMed: 19500159]
- Syrbe S, et al., 2015 De novo loss- or gain-of-function mutations in *KCNA2* cause epileptic encephalopathy. *Nat. Genet* 47, 393–399. [PubMed: 25751627]
- Sze CI, Su M, Pugazhenti S, Jambal P, Hsu LJ, Heath J, Schultz L, Chang NS, 2004 Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease. *J Biol Chem* 279, 30498–30506. [PubMed: 15126504]
- Tabarki B, Alhashem A, Alshahwan S, Alkuraya FS, Gedela S, Zuccoli G, 2015 Severe CNS involvement in *WWOX* mutations: Description of five new cases. *Am. J. Med. Genet. A* 167A, 3209–3213. [PubMed: 26345274]
- Ure J, Baudry M, Perassolo M, 2006 Metabotropic glutamate receptors and epilepsy. *J. Neurol. Sci* 247, 1–9. [PubMed: 16697014]
- Valduga M, Philippe C, Lambert L, Bach-Segura P, Schmitt E, Masutti JP, Francois B, Pinaud P, Vibert M, Jonveaux P, 2015 *WWOX* and severe autosomal recessive epileptic encephalopathy: first case in the prenatal period. *J. Hum. Genet* 60, 267–271. [PubMed: 25716914]
- Vezzani A, Sperk G, Colmers WF, 1999 Neuropeptide Y: emerging evidence for a functional role in seizure modulation. *Trends Neurosci.* 22, 25–30. [PubMed: 10088996]

- Vezzani A, French J, Bartfai T, Baram TZ, 2011 The role of inflammation in epilepsy. *Nat. Rev. Neurol* 7, 31–40. [PubMed: 21135885]
- Wang HY, Juo LI, Lin YT, Hsiao M, Lin JT, Tsai CH, Tzeng YH, Chuang YC, Chang NS, Yang CN, Lu PJ, 2012 WW domain-containing oxidoreductase promotes neuronal differentiation via negative regulation of glycogen synthase kinase 3beta. *Cell Death Differ.* 19, 1049–1059. [PubMed: 22193544]
- Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR, 1995 Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. *Nat. Genet* 11, 45–51. [PubMed: 7550313]
- Wei PC, Chang AN, Kao J, Du Z, Meyers RM, Alt FW, Schwer B, 2016 Long Neural Genes Harbor Recurrent DNA break Clusters in Neural Stem/Progenitor Cells. *Cell* 164, 644–655. [PubMed: 26871630]
- Wilbur C, Buerki SE, Guella I, Toyota EB, Evans DM, McKenzie MB, Datta A, Michoulas A, Adam S, Van Allen MI, Nelson TN, Farrer MJ, Connolly MB, Demos M, 2017 An Infant With Epilepsy and Recurrent Hemiplegia due to Compound Heterozygous Variants in ATP1A2. *Pediatr. Neurol* 75, 87–90. [PubMed: 28811059]
- Williams CA, Battaglia A, 2013 Molecular biology of epilepsy genes. *Exp. Neurol* 244, 51–58. [PubMed: 22178301]
- Xia K, Zhang J, Ahn M, Jha S, Crowley JJ, Szatkiewicz J, Li T, Zou F, Zhu H, Hibar D, Thompson P, Consortium E, Sullivan PF, Styner M, Gilmore JH, Knickmeyer RC, 2017 Genome-wide association analysis identifies common variants influencing infant brain volumes. *Transl. Psychiatry* 7, e1188. [PubMed: 28763065]
- Xie G, Harrison J, Clapcote SJ, Huang Y, Zhang JY, Wang LY, Roder JC, 2010 A new Kv1.2 channelopathy underlying cerebellar ataxia. *J. Biol. Chem* 285, 32160–32173. [PubMed: 20696761]
- Zaben MJ, Gray WP, 2013 Neuropeptides and hippocampal neurogenesis. *Neuropeptides* 47, 431–438. [PubMed: 24215800]
- Zhao C, Aviles C, Abel RA, Almli CR, McQuillen P, Pleasure SJ, 2005 Hippocampal and visuospatial learning defects in mice with a deletion of frizzled 9, a gene in the Williams syndrome deletion interval. *Development* 132, 2917–2927. [PubMed: 15930120]



Panels (A) and (B) show representative microphotographs illustrating the distribution of PV + interneurons in DG (dentate gyrus) and the CA1 and CA3 (cornu ammonis) subfields of the hippocampus of 2 wk. old *Wwox* WT(A1–A3) and *Wwox* KO(B1–B3) mice. The insets show magnified images of single interneuron from each subfield (marked with arrows). A paucity of PV+ neuronal cell bodies and processes can be appreciated in the various hippocampal regions of *Wwox* KO mice (B1–B3) versus comparable regions from *Wwox* WT control counterparts. Bar charts (C1–C3 and D) show stereological results comparing the number of PV+ interneurons in DG (C1), CA1 subfield (C2), CA3 subfield (C3), and the entire hippocampus (D). Bar graphs represent the average values of *Wwox* WT ($n = 7$) and *Wwox* KO ($n = 7$) mice as indicated. Error bars represent \pm SEM, * $p < .05$; ** $p < .005$, two tailed unpaired Student's *t*-test. DH, dentate hilus; GCL, granule cell layer.




Fig. 2. | *Wwox* KO mice hippocampi exhibit a decrease in NPY+ interneurons. Panels (A) and (B) show representative images illustrating the distribution of NPY+ interneurons in DG and the CA1 and CA3 subfields of the hippocampus of 2 wk. old *Wwox* WT(A1–A3) and *Wwox* KO(B1–B3) mice. A significant reduction in the number of NPY+ cells is apparent in the DG subfield of a *Wwox* KO mouse (B1) in comparison to the same region from a *Wwox* WT counterpart (A1). Bar charts (C1–C3 and D) compare the average number of NPY+ interneurons in DG (C1), CA1 subfield (C2), CA3 subfield (C2), and the entire hippocampus (D) from *Wwox* WT ($n = 6$) and *Wwox* KO ($n = 6$) mice as indicated. Error bars represent \pm SEM, * $p < .05$, two tailed unpaired Student's *t*-test. DH, dentate hilus; GCL, granule cell layer.




Fig. 3. | *Wwox KO* mice hippocampi exhibit increase in IBA-1+ cells indicating microglia activation.

Panels (A) and (B) display representative images illustrating the distribution and morphology of IBA-1+ microglial cells in the DG and CA1 and CA3 subfields of the hippocampus of 2 wk. old *Wwox WT* (A1–A3) and *Wwox KO* (B1–B3) mice. A significant increase in the area fraction (AF) occupied by IBA-1+ structures in CA1 and CA3 subfield as well as entire hippocampus can be observed in *Wwox KO* mouse. Bar charts (C1–C3 and D) compared the average AF occupied by IBA-1+ astrocytes in DG (C1), CA1 subfield (C2), CA3 subfield (C3), and the entire hippocampus (D) from *Wwox WT* (n = 6) and *Wwox KO* (n = 6) mice as indicated. Error bars represent \pm SEM, *p < .05, two tailed unpaired Student's t-test. DH, dentate hilus.




Fig. 4. |. *Wwox* KO mice hippocampi exhibit increase in GFAP+ astroglial activation as evidence of increase gliosis.

Panels (A) and (B) display representative microphotographs illustrating the distribution and morphology of GFAP+ astrocytes in the various hippocampal subfields of 2 wk. old *Wwox* WT(A1–A3) and *Wwox* KO mice (B1–B3). A considerable increase in the AF occupied by GFAP+ structures in the CA1 and CA3 subfields as well as the entire hippocampus is observed in *Wwox* KO mice. Bar graphs (C1–C3 and D) compare the average AF occupied by GFAP+ astrocytes in DG (C1), CA1 subfield (C2), CA3 subfield (C3), and the entire hippocampus (D) of *Wwox* WT ($n = 6$) and *Wwox* KO ($n = 8$) as indicated. Error bars represent \pm SEM, * $p < .05$, two tailed unpaired Student's t-test. (E) Expression of *Tnf-a* and *Il6* in *Wwox* KO mice hippocampi ($n = 4$). Y axis in the graph represents relative linear FC values with respect (w.r.t) to *Wwox* WT mice hippocampi ($n = 4$); error bars represent \pm SEM, * p value $< .05$, two tailed unpaired Student's t-test.




Fig. 5. | *Wwox* KO mice hippocampi show reduced expression of Gad65/67 isoforms.

(A) Immunoblot of glutamic acid decarboxylase (Gad) protein isoforms in *Wwox* WT and *Wwox* KO mice hippocampi tissue lysates as indicated. (B) Bar graphs representing the average densitometry immunoblot bands representing Gad65/67 protein expression, normalized to Actin loading control, in *Wwox* WT ($n = 5$) and *Wwox* KO ($n = 5$) mice. Error bars represent \pm SEM, *p value $< .05$, two tailed unpaired Student's t-test.




Fig. 6. |. Gene expression profile of *Wwox* KO vs. WT mice hippocampal neural stem cells neurospheres.

(A) Unsupervised clustering and heatmap for the 283 differentially expressed genes with \log_2 FC $> \pm 1$, p -value $< .005$, FDR < 0.05 comparing *Wwox* KO and *Wwox* WT mice hippocampi derived neurospheres. Red or green colors indicate differentially up or downregulated genes, respectively. The mean signals were background corrected and transformed to the \log_2 scale. (B) Bar graph representing functional annotations indicating enrichment for cognitive impairment, epilepsy and seizure related disorders as consequence of dysregulated gene expression in NSCs from *Wwox* KO mice with Z scores > 1 and p -value $< .00001$, numbers on the top of each bar represents the number of genes enriched in that specific category as per IPA analysis. (C, D) Relative expression of *Grin2C*, *Grm3*, and *Kcna2* as per RNA-Seq data, *Wwox* KO mice ($n = 2$) relative to *Wwox* WT ($n = 3$) (C), and as per qRT-PCR on RNA obtained from *Wwox* KO ($n = 4$) relative to *Wwox* WT ($n = 4$) hippocampi (D). Y axis in the RNA-Seq data graph (C) represents relative \log_2 FC values

while in hippocampi graph (D) it represents relative linear FC values, with respect to *Wwox* *WT* mice; error bars represent \pm SEM, *** $p < .0001$, two tailed unpaired Student's t-test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1
Dysregulated genes as per RNA-Seq analysis in *Wwox* KO derived neurospheres with relevance to epilepsy.

Complete list of 283 differentially expressed genes ($\log_2 FC > \pm 1$, $p \text{ value} < .005$, $FDR < 0.05$) between *Wwox* WT and *Wwox* KO groups is given in Supplementary Table 2.

Gene	Description	Log2 FC	p value	FDR	Function/relevance	References
Gabbr2	GABA B Receptor, 2	1.72	5.91E-10	1.98E-07	Heterodimerizes with GABBR1 participates in sustained inhibitory GABA-ergic neurotransmission	(Karlsson et al., 1992; Han et al., 2012)
Fgf1	Fibroblast Growth Factor 1	1.30	2.92E-10	3.71E-07	Involved with morpho-functional alterations in brain circuitries associated with epileptogenesis	(Riva et al., 1995; Paradiso et al., 2013)
Fzd9	Frizzled Receptor 9	1.2	4.80E-07	8.20E-04	Wnt signaling receptor in the brain, associated with Williams Beuren Syndrome	(Zhao et al., 2005)
Gabra2	GABA A Receptor, Alpha 2	1.15	7.01E-04	3.45E-02	Mutations in this gene are associated with epilepsy	(Hung et al., 2013; Srivastava et al., 2014; Orenstein et al., 2018)
Chl1	Cell Adhesion Molecule Like	1.01	6.53E-11	1.04E-07	Neural recognition molecule involved in signal transduction pathways; deletions of this gene likely responsible for mental defects in 3p syndrome	(Angeloni et al., 1999; Frints et al., 2003)
Kcna2	Voltage-Gated Potassium Channel	-1.45	4.68E-09	4.68E-09	Role in neuronal repolarization; loss- or gain-of-function mutations in <i>KCNV2</i> cause epileptic encephalopathy	(Pena and Coimbra, 2015; Syrbe et al., 2015; Corbett et al., 2016; Hundallah et al., 2016; Masnada et al., 2017; Sachdev et al., 2017)
Stx1b	Syntaxin 1B	-1.47	1.60E-04	1.07E-02	Role in excitatory pathway of synaptic transmission; known to be implicated in epilepsy and seizure disorder	(Lerche et al., 2001; Schubert et al., 2014)
Gabbr1	GABA B Receptor, 1	-1.48	1.49E-06	2.09E-04	Heterodimerizes with GABBR2 participates in sustained inhibitory GABA-ergic neurotransmission	(Karlsson et al., 1992; Han et al., 2012)
Kenj10	Potassium Channel, Inwardly Rectifying Subfamily J Member 10	-1.54	2.76E-04	1.60E-02	Responsible for the potassium buffering action of glial cells; mutations are associated with seizure and epilepsy syndromes	(Reichold et al., 2010; Sala-Rabanal et al., 2010; Freudenthal et al., 2011)
Alpl	Alkaline Phosphatase	-1.56	5.12E-08	1.04E-05	Tissue non-specific alkaline phosphatase; knock out in mice induces fatal seizure disorder	(Waymire et al., 1995)
Grm3	Glutamate Metabotropic Receptor 3	-1.61	8.21E-10	2.66E-07	Glutamate receptor; deregulation of GluR signaling functions may occur in some forms of epilepsy	(Meldrum, 1994; Ure et al., 2006)
Grin2b	Glutamate Ionotropic Receptor NMDA Subunit 2B	-2.14	2.75E-06	3.60E-04	Mutations are associated with early infantile epileptic encephalopathy	(Lemke et al., 2014; Platzer et al., 2017)
Arx	Aristaless Related Homeobox	-2.33	8.89E-06	1.01E-04	Homeodomain transcription factor; crucial role in cerebral development, loss of function mutations cause epilepsy and mental retardation	(Scheffer et al., 2002; Stromme et al., 2002; Gronskov et al., 2004)
Apoe	Apolipoprotein E	-2.64	9.36E-32	9.11E-28	Role in the fat metabolism; associated with Alzheimer's disease and epilepsy	(Busch et al., 2007)
Atpl2a2	ATPase Na+/K+ Transporting Subunit Alpha 2	-3.15	6.42E-16	5.68E-13	Role in establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane	(Jurkat-Rott et al., 2004; Wilbur et al., 2017)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Gene	Description	Log2 FC	p value	FDR	Function/relevance	References
Grin2c	Glutamate Ionotropic Receptor NMDA Subunit 2C	-3.22	6.55E-06	7.73E-04	NMDA receptors are crucial for neuronal communication, known to be involved in various neurological and psychiatric disorders	(Paoletti et al., 2013)